Figure 1.

HBD2 protects against V8-mediated barrier integrity damage. (a) Timeline of damage assay, with treatment conditions indicated. (b,c) HaCaT cells were treated with 0.5 µg/ml HBD2 or vehicle control for 24 h. Recombinant V8 (5 µg/ml) or PBS (vehicle control) was then added, and cells were incubated for a further 24 h before 5 random fields of view were imaged per condition by phase contrast microscopy. (b) Quantification of V8-mediated damage represented as % monolayer damage. Data shown as mean ± SEM for n = 8. Statistical analysis by paired one-way ANOVA with Repeated Measures (RM) multiple comparisons post-test. **p < 0.01 ***p < 0.005 ****p < 0.001. (c) Representative images of damage at 72 h (from n = 8), with barrier integrity damage “holes” indicated with white arrow heads. Scale bar represents 200 µm.